Finance

Lists
Why is 600664 up २.१०%?
Dive Deeper
600664:SHA
Harbin Pharmaceutical Group Co Ltd
CN¥ ६.३२
+२.१०%
(+०.१३) 1D
अक्टोबर १६, १५:००:०१ GMT+८  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600664...
Open
CN¥ ६.२६
High
CN¥ ६.७७
Low
CN¥ ६.१९
Mkt. cap
१५.५९ अरब
Avg. vol.
३८.७१ करोड
Volume
४१.२४ करोड
P/E ratio
३१.०८
52-wk high
CN¥ ९.८६
52-wk low
CN¥ २.८४
EPS
CN¥ ०.२०
Shares outstanding
२.५४ अरब
No. of employees
१० हजार
Open
CN¥ ६.२६
High
CN¥ ६.७७
Low
CN¥ ६.१९
Mkt. cap
१५.५९ अरब
Avg. vol.
३८.७१ करोड
Volume
४१.२४ करोड
P/E ratio
३१.०८
52-wk high
CN¥ ९.८६
52-wk low
CN¥ २.८४
EPS
CN¥ ०.२०
Shares outstanding
२.५४ अरब
No. of employees
१० हजार
News stories
From web sources and news partners
MarketBeat
MarketBeat
·
१२ मिनेट पहिले
Tenable (NASDAQ:TENB) Upgraded to "Strong-Buy" at Wall Street Zen
Simply Wall Street
Simply Wall Street
·
१ घण्टा पहिले
What AAON Bears Saw Before The Fall
Trefis
Trefis
·
१ घण्टा पहिले
1 S&P 500 Stock Hit A 52-Week Low On Friday
Profile
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
About Harbin Pharmaceutical Group Co Ltd
CEO-
Employees१० हजार
Founded१९८८
Headquarters-
Sector-
Websitehayao.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
३.९० अरब
३.९४ अरब
४.१८ अरब
४.१२ अरब
Cost of goods sold
२.९५ अरब
२.९६ अरब
३.१७ अरब
२.९६ अरब
Cost of revenue
२.९५ अरब
२.९६ अरब
३.१७ अरब
२.९६ अरब
Research and development expenses
३.३६ करोड
५.१३ करोड
२.७० करोड
३.३४ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७५.३५ करोड
८१.६० करोड
७२.१२ करोड
८०.३४ करोड
Operating expense
८३.८६ करोड
८९.७० करोड
७८.६६ करोड
८९.५९ करोड
Total operating expenses
३.७८ अरब
३.८५ अरब
३.९६ अरब
३.८६ अरब
Operating income
११.२३ करोड
८.८८ करोड
२१.९९ करोड
२६.४९ करोड
Other non operating income
४.६८ लाख
-१.३० करोड
-७९.६९ लाख
१२.०५ लाख
EBT including unusual items
११.९१ करोड
९.१७ करोड
२०.६४ करोड
३१.१४ करोड
EBT excluding unusual items
१०.९९ करोड
६.३७ करोड
२०.८१ करोड
२५.४३ करोड
Income tax expense
४.१३ करोड
३.४६ करोड
४.५४ करोड
६.३४ करोड
Effective tax rate
३४.६७%
३७.७५%
२१.९७%
२०.३७%
Other operating expenses
२.४७ करोड
२.९२ करोड
२.१९ करोड
५.४० करोड
Net income
६.८९ करोड
३.३० करोड
१६.११ करोड
२४.९२ करोड
Net profit margin
१.७७%
०.८४%
३.८६%
६.०५%
Earnings per share
-
-
-
-
Interest and investment income
४०.४९ लाख
३१.४१ लाख
४२.०० लाख
६१.१९ लाख
Interest expense
-१.११ करोड
-१.०८ करोड
-८०.०८ लाख
-१.०१ करोड
Net interest expenses
-७०.०२ लाख
-७६.२२ लाख
-३८.०८ लाख
-३९.८४ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
१६.६४ करोड
१४.३० करोड
२७.४२ करोड
३२.०७ करोड
Gain or loss from assets sale
३९.८६ लाख
-३८.२८ लाख
-
-३.५८ करोड
AI content may include mistakes. Learn more
Google एपहरू